文献速递中医内科中药与中成药合理使用

中药颗粒治疗武汉重型COVID-19的疗效与安全性:倾向性评分匹配回顾性研究

Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching.
PubMed 文献 · Phytomedicine · 2020-11-05

该单中心回顾性研究采用倾向性评分匹配法,比较中药颗粒联合常规治疗与单纯常规治疗对重型COVID-19患者的疗效与安全性。匹配后每组43例,结果显示中药颗粒未显著改善28天临床改善率,但降低了28天死亡率并缩短发热持续时间,同时D-二聚体升高更常见。

要点

  • 中药颗粒联合常规治疗未显著改善28天临床改善率(p=0.851)。
  • 中药颗粒组28天死亡率降低(p=0.049),发热持续时间缩短(4天 vs 7天,p=0.002)。
  • 中药颗粒组D-二聚体水平升高更常见(p=0.036),需关注纤溶风险。

核心结论

  • 对于重型COVID-19患者,中药颗粒联合常规治疗在临床改善方面未优于单纯常规治疗。
  • 中药颗粒的使用降低了28天死亡率并缩短了发热缓解时间。
  • 中药颗粒可能与纤溶风险升高相关。

研究设计与样本

  • 单中心回顾性研究,纳入2020年1月15日至3月30日武汉某定点医院的重型COVID-19患者。
  • 采用倾向性评分匹配(PSM),按1:1匹配中药颗粒联合常规治疗组与单纯常规治疗组,每组43例。
  • 匹配后患者年龄65.6(57-70)岁,男性占45%。

主要发现

  • 中药颗粒组与常规治疗组在28天临床改善率上无显著差异(p=0.851)。
  • 中药颗粒组28天死亡率降低(p=0.049)。
  • 中药颗粒组发热持续时间缩短(4天 vs 7天,p=0.002)。
  • 咳嗽持续时间、呼吸困难持续时间及CT肺部病灶比例差异无统计学意义。
  • 中药颗粒组D-二聚体水平升高更常见(p=0.036)。

关键数值与推荐

  • 主要结局为28天内临床改善时间,定义为改良六分类序贯量表较基线下降两级或28天前出院。
  • 28天临床改善率比较p=0.851;28天死亡率比较p=0.049;发热持续时间比较p=0.002;D-二聚体升高比较p=0.036。

临床怎么用

  • 对重型COVID-19患者,中药颗粒联合常规治疗可能降低28天死亡率并缩短发热时间。
  • 使用中药颗粒时应监测D-二聚体等纤溶指标,警惕纤溶风险。

局限性

  • 本研究为单中心回顾性研究,样本量有限(每组43例)。
  • 研究设计无法完全排除残余混杂,因果推断受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chinese herbal medicine (CHM) has been used for severe illness caused by coronavirus disease 2019 (COVID-19), but its treatment effects and safety are unclear. PURPOSE: This study reviews the effect and safety of CHM granules in the treatment of patients with severe COVID-19. METHODS: We conducteda single-center, retrospective study on patients with severe COVID-19 in a designated hospital in Wuhan from January 15, 2020 to March 30, 2020. The propensity score matching (PSM) was used to assess the effect and safety of the treatment using CHM granules. The ratio of patients who received treatment with CHM granules combined with usual care and those who received usual care alone was 1:1. The primary outcome was the time to clinical improvement within 28 days, defined as the time taken for the patients' health to show improvement by decline of two categories (from the baseline) on a modified six-category ordinal scale, or to be dischargedfrom the hospital before Day 28. RESULTS: Using PSM, 43 patients (45% male) aged 65.6 (57-70) yearsfrom each group were exactly matched. No significant difference was observed in clinical improvement of patients treated with CHM granules compared with those who received usual (p = 0.851). However, the use of CHM granules reduced the 28-day mortality (p = 0.049) and shortened the duration of fever (4 days vs. 7 days, p = 0.002). The differences in the duration of cough and dyspnea and the difference in lung lesion ratio on computerized tomography scans were not significant.Commonly,patients in the CHM group had an increased D-dimer level (p = 0.036). CONCLUSION: Forpatients with severe COVID-19, CHM granules, combined with usual care, showed no improvement beyond usual care alone. However, the use of CHM granules reduced the 28-day mortality rate and the time to fever alleviation. Nevertheless, CHM granules may be associated with high risk of fibrinolysis.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Wang Y, Liu Y, Lv Q, et al. Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching. Phytomedicine. 2020. PMID: 33637412. doi:10.1016/j.phymed.2020.153404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。